Menactra Sanofi Pasteur - Treatment for Protection Against Meningococcal Disease
Menactra is the first quadrivalent conjugate vaccine licensed in the U.S. for the prevention of meningococcal disease and is designed to offer protection against four serogroups of Neisseria meningitidis (A, C, Y, W-135), the bacterium that causes meningococcal infection.Posted: January 2005
Related articles
- FDA Approves Menactra to Prevent Meningococcal Disease in Infants and Toddlers - April 25, 2011
- Advisory Panel Recommends FDA Licensure of Aventis' Menactra Vaccine for Protection Against Meningococcal Disease - September 22, 2004
Menactra (meningococcal conjugate vaccine) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
